Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | CCR4 | P51679 | 8/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18560 | 0.87 | GRIN1 (0.47) | BUB1GRIN1GRIN2BCCR4ROCK2 | |
| SCHEMBL18001 | 0.83 | CCR4 (0.56) | CCR4 | |
| SCHEMBL185210 | 0.82 | CCR4 (0.42) | BUB1GRIN1GRIN2BCCR4ROCK2 | |
| SCHEMBL185631 | 0.82 | CCR4 (0.41) | BUB1GRIN1GRIN2BCCR4ROCK2 | |
| SCHEMBL186021 | 0.82 | GRIN1 (0.44) | BUB1GRIN1GRIN2BEGFRERBB2 | |
| SCHEMBL186627 | 0.82 | CYP19A1 (0.43) | BUB1GRIN1GRIN2BEGFRERBB2 | |
| SCHEMBL185722 | 0.82 | CCR4 (0.54) | CCR4CYP19A1 | |
| SCHEMBL185508 | 0.79 | CCR4 (0.60) | CCR4 | |
| SCHEMBL186393 | 0.79 | CSF1R (0.47) | CCR4 | |
| SCHEMBL30129 | 0.78 | CCR4 (0.50) | BUB1CCR4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738962-B1 | SALTS OF A COMPOUND AND USE THEREOF | MEDSPRING INTERNATIONAL LTD (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-3738962-B1 | SALTS OF A COMPOUND AND USE THEREOF | MEDSPRING INTERNATIONAL LTD (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-110028501-B | Compound and preparation method and application thereof | 迈德欣国际有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20210078985-A1 | COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | MEDSPRING INTERNATIONAL LIMITED (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20210078985-A1 | COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | MEDSPRING INTERNATIONAL LIMITED (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3738962-A1 | COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Medspring International Limited (CN) | 2020-11-18 | — | — | EP | disclosed |
| EP-3738962-A1 | COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Medspring International Limited (CN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| WO-2012025473-A1 | CC.CHEMOKINE RECEPTOR 4 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078985-A1 | COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | CCR4, CCR1, CCL11 | BUB1 3523/4885GRIN1 1430/4885GRIN2B 2656/4885 |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | BUB1 1013/4885GRIN1 1722/4885GRIN2B 1429/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | BUB1 844/4885GRIN1 3405/4885GRIN2B 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.